Breast

11086 11-PIR-11: The BEACON Study (Breast Cancer Outcomes With Nktr-102): A Phase 3 Open-Label, Randomized, Multicenter Study Of NKTR-102 Versus Treatment Of Physician’s Choice (TPC) In Patients With Locally Recurrent Or Metastatic Breast Cancer Previously Treated With An Anthracycline, A Taxane, And Capecitabine

11176 A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer

10065 A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination with Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (E7389-A001-212)

NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

RTOG 07173 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (RTOG)

06185 - Randomized Phase II Trial of Letrozole with or without Dasatinib as First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic

NSABP B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Please contact the NYOH Research Department for more information on clinical trials at (518) 489-0044 ext. 1239